FolioLanternBeta
TVTXTravere Therapeutics, Inc.

Christopher Cline

Chief Financial Officer at Travere Therapeutics, Inc., as of Sep 17, 2026Sold $4.6M of stock in the past 12 months: 94% under a disclosed plan and 6% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
88K
shares held after the latest filing, Travere Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
91K
shares sold, past 12 months
10
days with sales
$3.1M
largest single day, Sep 15, 2026
1
company filed for

Share of stake sold at Travere Therapeutics, Inc. is not shown: most of their shares vested during the period, so a percentage would mislead. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
OctNovDec 2025: $700K under a disclosed planDecJanFeb 2026: $56K under a disclosed planFeb 2026: $233K to cover taxesFebMarApr 2026: $349K under a disclosed planAprMay 2026: $115K under a disclosed planMayJunJulAugSep 2026: $3.1M under a disclosed planSep 2026: $43K to cover taxes$3.2MSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Travere Therapeutics, Inc. (TVTX)Chief Financial OfficerSep 1, 2022Sep 17, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.